Company Encyclopedia
View More
name
Schrodinger
SDGR.US
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
70.40 B
SDGR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care TechnologyIndustry
Industry Ranking12/44
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-45.67%E
    • Profit Margin-68.49%E
    • Gross Margin51.61%B
  • Growth ScoreB
    • Revenue YoY32.90%A
    • Net Profit YoY0.89%C
    • Total Assets YoY-2.34%D
    • Net Assets YoY-28.50%E
  • Cash ScoreC
    • Cash Flow Margin-146.00%D
    • OCF YoY32.90%A
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreC
    • Gearing Ratio50.84%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Schrodinger (SDGR) Gets a Buy from KeyBanc

    KeyBanc's Scott Schoenhaus maintains a Buy rating on Schrodinger (SDGR) with a $28 price target. Schrodinger has a Moderate Buy consensus with a $26.50 price target. Schoenhaus, focusing on healthcare stocks, has a -9.3% average return and a 31.11% success rate on recommendations.

    Tip Ranks·
    US
    SDGR
    +3.83%
    Tip Ranks·
    US
    SDGR
    +3.83%

    What You Can Learn From Schrödinger, Inc.'s (NASDAQ:SDGR) P/S After Its 27% Share Price Crash

    Schrödinger, Inc. (NASDAQ:SDGR) experienced a 27% share price drop, raising concerns despite its high P/S ratio of 4.7x compared to the industry average of 2.6x. The company's strong revenue growth, with a 33% increase last year and 51% over three years, supports its high P/S. Analysts predict 17% annual growth, surpassing the industry's 13%. Shareholders remain optimistic about future revenues, maintaining the high P/S despite the price drop.

    Simplywall·
    US
    SDGR
    +3.83%
    Simplywall·
    US
    SDGR
    +3.83%

    Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Rating of "Hold" from Analysts

    Schrodinger, Inc. (NASDAQ:SDGR) has received an average rating of 'Hold' from seven research firms. The stock has one sell, three hold, and three buy recommendations. The average 12-month price target is $26.00. Recent analyst actions include downgrades and price target reductions. Insider Margaret Dugan sold shares, and institutional investors have adjusted their positions. Schrodinger reported better-than-expected Q3 earnings with a 53.9% revenue increase. The company focuses on software and drug discovery.

    Market Beat·
    US
    SDGR
    +3.83%
    Market Beat·
    US
    SDGR
    +3.83%

    Could Copernic Catalyst Progress Shift Schrödinger’s (SDGR) Long-Term Growth Thinking?

    Schrödinger reported strong Q3 results with significant revenue growth from its software and drug discovery segments, alongside a narrowed net loss and revised 2025 guidance. The collaboration with Copernic Catalysts achieved a major milestone in ammonia catalyst development, potentially enhancing industrial profits and reducing emissions. Despite positive signals, investors should remain cautious of ongoing pressures on software revenue growth and profitability. Schrödinger's projected revenue by 2028 is $396.6 million, with a fair value estimate between $27.30 and $43.20, indicating a potential upside of 49% from its current price.

    Simplywall·
    US
    SDGR
    +3.83%
    Simplywall·
    US
    SDGR
    +3.83%

    Schrodinger (SDGR) Gets a Hold from Goldman Sachs

    Goldman Sachs analyst Andrea Newkirk has maintained a Hold rating on Schrodinger (SDGR) with a price target of $21.00. Newkirk is noted for a 29.2% average return and a 90% success rate. Additionally, Bank of America Securities also issued a Hold rating, while TD Cowen maintained a Buy rating on November 5.

    Tip Ranks·
    US
    SDGR
    +3.83%
    Tip Ranks·
    US
    SDGR
    +3.83%
    © 2025 Longbridge｜Disclaimer